Combination drug use and risk for fetal harm.
Drinking of alcoholic beverages
Drinking of alcoholic beverages (Research)
Drugs (Health aspects)
Women (Health aspects)
Chen, Wei-Jung A.
Maier, Susan E.
|Publication:||Name: Alcohol Research & Health Publisher: U.S. Government Printing Office Audience: Academic; Professional Format: Magazine/Journal Subject: Health Copyright: COPYRIGHT 2011 U.S. Government Printing Office ISSN: 1535-7414|
|Issue:||Date: Spring, 2011 Source Volume: 34 Source Issue: 1|
|Topic:||Event Code: 310 Science & research|
|Product:||Product Code: 2830000 Drugs & Pharmaceuticals; 2834000 Pharmaceutical Preparations; 2834190 Metabolic Agents; 2834199 Metabolic Agents NEC NAICS Code: 3254 Pharmaceutical and Medicine Manufacturing; 325412 Pharmaceutical Preparation Manufacturing SIC Code: 2834 Pharmaceutical preparations|
|Geographic:||Geographic Scope: United States Geographic Code: 1USA United States|
Alcohol and other drugs are frequently used in combination (Martin
2008; National Institute on Alcohol Abuse and Alcoholism 2008). Based on
data from the National Epidemiologic Survey on Alcohol and Related
Conditions, Falk and colleagues (2006, 2008) reported that 21.7 percent
of the sampled population used both alcohol and tobacco and 5.6 percent
used alcohol and another drug. Among women aged 18 to 24 the rates were
25.5 percent and 12.5 percent, respectively. Individually, alcohol,
tobacco products, and a number of illicit drugs (such as cocaine or
amphetamine) are known to be harmful to the developing fetus during
pregnancy. Determining the additional harm resulting from polydrug use
during pregnancy is an exceptionally challenging task. The unpredictable
interactive (either additive or synergistic) effects of the drugs used
simultaneously have far-reaching implications on child health and
development given the pervasive use of multiple drugs in our society.
Changes in how drugs are absorbed, distributed, metabolized, and eliminated (i.e., pharmacokinetics) may help explain why polydrug use is dangerous to fetal development. Pharmacokinetic interaction is the process that occurs when two or more drugs are in the system at the same time. Although the pharmacokinetics of individual drugs may be well characterized, when the drugs are combined, one drug can seriously and unpredictably alter the concentration, bioavailability (the rate of a drug entering the bloodstream), and net effect of the other drug. Alternatively, the combination of drugs can alter the bioavailability of either or both drugs or form a metabolite more toxic than either of the parent compounds. For example, several well-known over-the-counter medications, such as aspirin, Tagamet[R] (cimetidine), and Zantac[R] (ranitidine), interact with alcohol metabolism leading to a higher level of blood alcohol concentration (BAC) (Baraona et al. 1994; Fraser 1998; Gentry et al. 1999). BAC levels for a given dose of alcohol are known and predictable; when another drug is added, alcohol metabolism is altered in an unpredictable manner. Given that BAC is a reliable predictor of the severity of alcohol-mediated brain injury in pre-clinical studies (Bonthius and West 1988, 1990), any drug that interferes with alcohol metabolism and results in an increase in BAC may be a potential cofactor in increasing alcohol-mediated damage.
In another example of the effects of combined drug use, Johnson and colleagues (1991) showed that cigarette smoking significantly reduced peak BAC in humans, and recent preclinical studies have reliably reproduced this finding (Gilbertson and Barron 2005; Parnell et al. 2006). Reduced BAC under the influence of nicotine presents a conundrum. Although decreasing BAC in the presence of nicotine may suggest a smaller injurious effect from alcohol, if someone desires to experience the "high" from alcohol or to drink to the point of inebriation, this decrease in BAC may promote additional alcohol use. This in turn may lead to an accumulation of acetaldehyde, an active and toxic metabolite of alcohol that exerts further damage to the physiological system, including the developing fetus.
As a final example, the interaction of alcohol and cocaine has been shown to be more harmful than the use of each drug individually because of the formation of the highly toxic metabolite cocaethylene (McCance et al. 1995; Pennings et al. 2002). Cocaethylene is an active metabolite of cocaine (Faroog et al. 2009; Patel et al. 2009), and it may account for the prolonged euphoria that occurs after concurrent use of alcohol and cocaine (McCance-Kate et al. 1998). Although clinical data regarding the negative effects of cocaethylene on fetal development are limited, the surviving offspring of mothers co-abusing alcohol and cocaine have shown neurobehavioral deficits (Singer et al. 2000). Moreover, preclinical studies using neonatal rats have shown toxic effects of the administration of cocaethylene on brain development (Chen and West 1997).
Potential harm to the developing fetus resulting from polydrug use during pregnancy is an important area of drug abuse research. Exploring the effects of each drug alone on the developing fetus does not capture the essence of the clinical condition. Studies on interactive effects of polydrug use fill a void in the scientific literature and highlight the importance of recognizing polydrug use during pregnancy as a significant maternal risk factor for fetal and child development and health. Research on how alcohol interacts with other drugs and how such interactions may adversely affect the developing brain will lead to a better categorization of the known detrimental effects from gestational polydrug use and a more focused understanding of the methods to avert or treat the outcomes.
BARAONA, E; GENTRY, R.T.; LIEBER, C.S. Bioavailability of alcohol: role of gastric metabolism and its interaction with other drugs. Digestive Disorders 12:351-367, 1994. PMID: 7712617
BONTHIUS, D.J., AND WEST, J.R. Blood alcohol concentration and microencephaly: A dose-response study in the neonatal rat. Teratology 37:223-231, 1988. PMID: 3368876
BONTHIUS, D.J., AND WEST, J.R. Alcohol-induced neuronal loss in developing rats: increased brain damage with binge exposure. Alcoholism: Clinical and Experimental Research 14:107-118, 1990. PMID: 1689970
CHEN, W.-J.A., AND WEST, J.R. Cocaethylene exposure during the brain growth spurt period: brain growth restrictions and neurochemistry studies. Developmental Brain Research 100:220-229, 1997. PMID: 9205812
FALK, D.; Yi, H-Y; AND HILLER-STURMHOFEL, S. An epidemiologic analysis of co-occurring alcohol and tobacco use and disorders: Findings from the National Epidemiologic Survey on Alcohol and Related Conditions. Alcohol Research & Health 29: 162-171, 2006.
FALK, D.; Yi, H-Y; AND HILLER-STURMHOFEL, S. An epidemiologic analysis of co-occurring alcohol and drug use and disorders: Findings from the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC). Alcohol Research &Health 31: 100-110, 2008. PMID: 17373404
FAROOQ, M.U.; BHATT, A.; AND PATEL, M. Neurotoxic and cardiotoxic effects of cocaine and ethanol. Journal of Medical Toxicology 5:134-138, 2009. PMID: 17373404
FRASER, A.G. Is there an interaction between H2-antagonists and alcohol? Drug Metabolism and Drug Interactions 14:123-145, 1998. PMID: 10366990
GENTRY, R.T.; BARAONA, E.; AMIR, I.; ET AL. Mechanism of the aspirin-induced rise in blood alcohol levels. Life Science 65:2505-2512, 1999. PMID: 10622235
GILBERTSON, R.J.; BARRON, S. Neonatal ethanol and nicotine exposure causes locomotor activity changes in preweaning animals. Pharmacology, Biochemistry, and Behavior 81:54-64, 2005. PMID: 15894064
Johnson, R.D.; Horowitz, M.; Maddox, A.F.; et al. Cigarette smoking and rate of gastric emptying: Effect on alcohol absorption. British Medical Journal 302:20-23, 1991. PMID: 1991182
MARTIN, C.S. Timing of alcohol and other drug use. Alcohol Research & Health 31:96-99, 2008.
McCance, E.F.; Price, L.H.; Kosten, T.R.; and Jatlow, P.I. Cocaethylene: Pharmacology, physiology and behavioral effects in humans. Journal of Pharmacology and Experimental Therapy 274:215-223, 1995. PMID: 7616402
McCance-Katz, E.F.; Kosten, T.R.; and Jatlow, P.I. Concurrent use of cocaine and alcohol is more potent and potentially more toxic than use of either alone: A multiple-dose study. Biological Psychiatry 44:250-259, 1998. PMID: 9715356
National Institute on Alcohol Abuse and Alcoholism. Alcohol and Other Drugs. Alcohol Alert (No. 76, 2008). US Department of Health & Human Services. Rockville, MD: National Institute on Alcohol Abuse and Alcoholism, 2008.
PARNELL, S.E.; WEST, J.R.; AND CHEN, W.-J.A. Nicotine decreases blood alcohol concentrations in adult rats: A phenomenon potentially related to gastric function. Alcoholism: Clinical and Experimental Research 30:1408-1413, 2006. PMID: 16899044
PATEL, M.B.; OPREANU, M.; SHAH, A.J.; ET AL. Cocaine and alcohol: A potential lethal duo. American Journal of Medicine 122:e5-e6, 2009. PMID: 19114159
PENNINGS, E.J.; LECCESE, A.P.; AND WOLFF, F.A. Effects of concurrent use of alcohol and cocaine. Addiction 97:773-783, 2002. PMID: 12133112
SINGER, L.T.; ARENDT, R.; MINNES, S.; ET AL. Neurobehavioral outcomes of cocaine-exposed infants. Neurotoxicology and Teratology 22:653-666, 2000. PMID: 11106858
WEI-JUNG A. CHEN, PH.D., is an associate professor in the Department of Neuroscience and Experimental Therapeutics, Texas A&M Health Science Center College of Medicine, College Station, Texas.
SUSAN E. MAIER, PH.D., is a scientific initiatives manager, Office of Initiative Development, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland.
|Gale Copyright:||Copyright 2011 Gale, Cengage Learning. All rights reserved.|